SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug
GOVX: 35% | Roth MKM Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $20
CFB: -12% | CrossFirst Bankshares shares are trading lower. The company reported Q2 financial results.
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/11/2024 | $15.00 | Buy | Alliance Global Partners | |
| 9/10/2024 | $21.00 | Neutral → Buy | Janney | |
| 7/16/2024 | $20.00 | Buy | ROTH MKM | |
| 2/21/2024 | Neutral | Janney | ||
| 1/24/2024 | $16.00 → $18.00 | Equal-Weight → Overweight | Stephens | |
| 1/5/2024 | $16.00 | Mkt Perform → Outperform | Raymond James | |
| 1/5/2023 | Outperform → Mkt Perform | Raymond James | ||
| 10/6/2022 | $18.00 → $16.00 | Strong Buy → Outperform | Raymond James |
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax's dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL). Based on the interim analysis of immune responses from the patients enrolled to date, the DSMB determined that, while the mRNA control arm of the study failed to meet the prede
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available
CHAMPAIGN, Ill. and LEAWOOD, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- First Busey Corporation ("Busey") (NASDAQ:BUSE), the holding company for Busey Bank, and CrossFirst Bankshares, Inc. ("CrossFirst") (NASDAQ:CFB), the holding company for CrossFirst Bank, jointly announced today the signing of a definitive agreement and plan of merger, pursuant to which CrossFirst will merge with and into Busey (the "Merger") in an all-common stock transaction valued at approximately $916.8 million, based on Busey's closing stock price of $27.39 as of August 26, 2024. The combined company, which will operate under the Busey brand, will have approximately $20 billion in total assets, approximately $17 billi
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
DEFR14A - Silo Pharma, Inc. (0001514183) (Filer)
DEFM14A - CROSSFIRST BANKSHARES, INC. (0001458412) (Filer)
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology. Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear
EF Hutton analyst Jason Kolbert initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $18.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow traded down 0.91% to 40,293.66 while the NASDAQ fell 0.70% to 17,746.27. The S&P 500 also fell, dropping, 0.61% to 5,510.84. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks Delivering High-Dividend Yields Leading and Lagging SectorsHeath care shares jumped by 0.5% on Thursday. In trading on Thursday, information technology shares fell by 1%. Top Headline Netflix Inc. (NASDAQ:NFLX) posted better-than-expected earnings and sales results for its second quarter, after the closing bell on Thursday. The company ende
Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00
Janney upgraded CrossFirst Bankshares from Neutral to Buy and set a new price target of $21.00
ROTH MKM initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $20.00
4 - CROSSFIRST BANKSHARES, INC. (0001458412) (Issuer)
4 - CROSSFIRST BANKSHARES, INC. (0001458412) (Issuer)
4 - CROSSFIRST BANKSHARES, INC. (0001458412) (Issuer)
4 - CROSSFIRST BANKSHARES, INC. (0001458412) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G/A - CROSSFIRST BANKSHARES, INC. (0001458412) (Subject)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)